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Screening for breast cancer
To the Editor: Professor Dent and Dr Panieri1 wrote an
excellent summary of many of the issues surrounding breast
screening and highlighted many of the problems in trying to
identify a commonsense approach. One can find a trial to
support almost any viewpoint.
For a disease to be amenable to screening, it should fulfil
certain criteria which include: (i) it should be a common
disease in the population to be screened; (ii) there should be
benefit from earlier diagnosis; and (iii) there should be a period
in which the disease can be detected before it is detected in the
normal course of events.
Clearly breast cancer in women aged over 50 fulfils the first
two criteria, but it is the third point that is inconsistent with the
3-yearly programme proposed in the UK. The ‘sojourn’ time is
the duration of time that an occult tumour can be detected
before the onset of symptoms. Applying this to breast cancer
(for the average non-screening-detected breast cancer of 1 - 2
cm) it has been estimated as 3.3 years in women aged 50 - 59
years. It is therefore illogical to propose 3-yearly screening in
this age group, and 2-yearly mammograms and yearly clinical
examination would be more suitable. 
The reason the UK selected 3 years was based on costing as
screening is funded by government and the cost of a missed
cancer was less than the cost of 2-yearly screening of the
population in general. As ‘breast screening’ in South Africa is
individually funded, 2-yearly mammograms for the over-50-
year-old would be a more appropriate recommendation.
In an excellent overview entitled ‘Limitations in the
interpretation of the mammography trials’ (San Antonio Breast
Cancer Symposium, December 2002), Professor I Craig
Henderson stated that all the studies used mammography
techniques that would be considered inferior today. He went
on to say that it is assumed that an inverse linear relationship
exists between tumour size and reduction of mortality. At
present, we do not know whether this is correct, therefore we
need to continue with the public health recommendations in
place. Recommendations from the USA are yearly
mammography, those from the UK 3-yearly mammography.
Until newer techniques that take into consideration increasing
knowledge of tumour biology are proven, it would seem
prudent that we should settle on 2-yearly mammograms which
fit into the natural history of the disease.
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To the Editor: The editorial in the May SAMJ1 by Dent and
Panieri was not only prominently placed in the journal, but
also earned a banner headline on the cover. Much of what was
written is highly controversial, misleading and unusual for a
publication in a peer-reviewed journal of such eminence as the
SAMJ.
Firstly, the work of Olsen and Gotzsche2 and their
publications including the Cochrane group3 in the Lancet in
2000 and 2001 have been widely discussed and analysed and
most responsible scientists have denigrated their conclusions,
so much so that not one country or major medical
school/institution/learned society has changed its attitude or
practice with regard to breast screening. Their work is seriously
flawed and provides no grounds for the scientific community
to alter its conclusions that breast screening results in a
substantial reduction in breast cancer mortality. I refer you
particularly to the 4th Milan Breast Cancer Meeting, and also to
an excellent review on mass breast screening by Peter Boyle as
published in The Breast in December 20034  and presented at the
St Gallen Conference on the Primary Therapy of Early Breast
Cancer.
There is no longer any controversy concerning mass
screening as there is incontrovertible proof that screening is
beneficial and significantly reduces the death rate from breast
cancer.5-8 There is also no statistical or clinical evidence that
clinical breast examinations and breast self-examination
influence the detection of breast cancer or affect its death rate
as these cannot detect early cancers as well as mammography
does.
Yes, mammography can be criticised and the necessity for
high quality needs no further discussion. In the USA and
Sweden, for example, mammographers have to be additionally
qualified and certified as do their departments, equipment and
quality control measures by legislation. The quality issue was
well brought out in the Canadian Trial where this factor
considerably altered their conclusions.
Dent and Panieri complain of the high costs of false-positive
mammograms. How is the value of a human life measured? Is
$1 200 000 expensive in saving a human being? Ask a relative
of that individual. Mammograms, FNAs and other
percutaneous diagnostic procedures are cheap and do not
remove a breadwinner from her job. Why don’t they rather
teach surgeons to avoid unnecessary breast surgery requiring
hospital admission? Far too many diagnostic surgical biopsies
are being done on women who have no disease at all, a large
number of whom have not had a mammogram before surgery.
What of mature women who are subjected to plastic surgical
breast procedures without prior mammography being done?
Investigation and treatment of breast diseases is now a
multidisciplinary endeavour requiring surgeons, radiologists
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and pathologists/cytologists to work in unison as a team. This
gives the patient the best deal and minimises the possibility of
the dreaded delayed cancer diagnosis — a serious error and
one that leads to the highest volume of litigation.
It has been clearly shown and agreed upon by the scientific
community in numerous large demographic trials that
screening mammography conclusively reduces the death rate
from breast cancer significantly, most trials showing this to be
in the order of 20 - 25%.
I resent strongly the implication that mammography
screeners are members of the ‘screening industry’. I would like to
see Dent and Panieri spend some time in a busy radiology or
mammography department to see the costs involved and the level
of sophistication of the equipment and staff, and to realise the level
of anxiety in the patients who all fear breast cancer, so often
unnecessarily. I would have hoped that their experience of
mammography and radiologists and other breast experts would
have given them a better insight into the scourge of breast cancer,
its rising incidence and the true value of early diagnosis.
I end with a quote from Boyle (which could be modified for
underprivileged South Africans): ‘Every women has the right
to participate in an organized breast screening programme
with high quality standards and audit built in. To discourage
an early detection procedure which has been shown in trial
after trial to reduce breast cancer mortality, on the basis of an
error prone review in a field in which one is not an expert,
seems to be questionable in the extreme.’
Paul Sneider
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To the Editor: I refer to the recent editorial by Dent and
Panieri1 on screening for breast cancer.
Screening for disease differs from the diagnostic testing of
symptomatic individuals in ways that have scientific, economic
and ethical consequences. It is perfectly just and necessary that
screening mammography be constantly re-evaluated for its
scientific and economic validity.
Your introduction of the topic to the Journal with a front
cover banner, editorial and Editor’s Choice insert makes
obvious your concern for the subject. This is laudable. As is the
statement by Dent and Panieri: ‘Nonetheless, it must also be
regarded as incontrovertibly evident that mammographic
screening saved women’s lives. All but one trial show
reduction in breast cancer death, and the meta-analyses
robustly support this.’
However, readers must be asking themselves, as I did, why
the authors of the editorial have chosen to describe proponents
of breast cancer screening with the pejorative phrase ‘members
of the screening industry’?
To describe the article by Gotzsche and Olsen2 with the
words ‘The Cochrane Group has also recently questioned the
validity . . .’ is erroneous.3 The article was published in the
Lancet in 2000, the two are on the staff of the Cochrane Library,
but the Cochrane Group Editors in fact refused to support their
conclusions without modifications. And the trials they referred
to were conducted in the 1970s and 1980s.
To do it twice — ‘The most recent criticism has been in the
form of an analysis of the Swedish trials by the Cochrane
group . . . ‘ — must be seen as deliberately misleading.
It is not my intention to respond by pointing out all the other
obviously biased opinions expressed in the editorial. Let me
rather place before your readers some other considerations that
may influence their decision whether or not to recommend
mammographic screening to their patients.
No sensible discussion of screening mammography in South
Africa can be conducted without entering this caveat: All the
references to screening mammography in the literature are to
mass screening mammography programmes, usually state-
sponsored or third party-paid. The shortcomings of mammo-
graphy — the perceived harms and costs per life saved — are
the shortcomings of mass screening mammography.
There is no such programme here, nor is any proposed. In
South Africa mammography is individualised. The benefits of
this individualisation are considerable.
The addition of a physical examination by the radiologist
reading the films and whole breast ultrasound (US)4 gives
increased sensitivity and a high negative predictive value.
Under these circumstances a normal examination and
mammogram presents the ideal opportunity to teach the
patient breast self-examination.
The accent is placed firmly on the positive aspects; the
patient is encouraged not to make a monthly search for disease
but rather a monthly affirmation of normalcy.
Patients frequently seek information regarding risk factors
and breast cancer. This provides an opportunity to point out
the benefits of a proper diet and exercise programme and the
risks associated with obesity.
This ‘hands on’ approach enables the radiologist to perform
percutaneous image-guided diagnostic biopsies when cancer is
suspected or when the patient’s anxiety is such that
reassurance alone will not allay her fears.
It may also be curative as in the case of cysts.
The maligned Swedish trials have in fact added a great deal
to our understanding of the biology of the group of diseases
referred to by the term breast cancer.5 The co-operative efforts
of their radiologists, pathologists and surgeons have
demonstrated a spectrum of disease with differing properties
and propensities to become invasive. The majority of breast
cancers are progressive but some are systemic from the outset,
thus explaining some of the deficiencies of past trials and their
analyses.
With regard to screening intervals, keep the following
considerations in mind:
• Risk for breast cancer varies with age, ethnicity, family and
obstetric history.
• The majority of screen-detected cancers are found in
individuals with no risk factors.
• While incidence rises with age, mortality decreases over the
age of 55 years.
• Younger women frequently have more aggressive tumour
biology.
• Breast cancers are progressive; cancers undetected in the
younger woman are more likely to become invasive.
• Younger women are more likely to have dense breast tissue
and will especially benefit from the addition of US
screening.
The  recommended screening intervals are therefore:
• Baseline mammogram and breast self examination
instruction between 35 and 40 years.
• 40 - 55 years: mammograms every 12 - 18 months
depending on risk profile.
• 55 years and over: mammograms every 18 - 24 months.
• It is also recommended that all patients have physical
examinations by their medical advisors between
mammograms.
A reduction in mortality has long been considered the most
valid endpoint in breast cancer screening. It is not the only
benefit, however.6
• The 10-year fatality rate is reduced by 50% in screen-
detected cancers.
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• Early, preclinical detection has enabled less extensive
surgery, and less need for cytotoxic chemotherapy.
• There has been a consistent downsizing of breast cancers
detected in screening programmes.
• Fewer screen-detected cancers are node positive.
• Ductal carcinoma in situ (DCIS) is found more frequently in
screened populations.
While not all DCIS becomes invasive, all invasive cancers
begin in situ. Prevention of invasive cancers by local excision
mimics carcinoma prevention by procedures such as removal
of colonic polyps, cervix cancer prevention by eradicating
dysplasia and carcinoma in situ, excision of dysplastic naevi or
removal of mucosal in situ lesions in the head and neck.
Pre-operative information gained from image-guided biopsy
staging and receptor status determination replaces the
uncertainty previously experienced by the patient sent for
excision biopsy. Treatment strategies can be discussed and
tailored to the patient’s circumstances, before surgery.
Mammography is not an exact science, however. Factors that
will improve sensitivity and specificity include training of
radiologists and quality control; the needs of women remote
from mammography facilities must be addressed. A collabo-
rative  approach by those of us involved in breast cancer
detection and treatment will ultimately benefit all the women
of South Africa.
The authors of your editorial appear to be barking up the
wrong tree and at the same time complaining about the noise.
Harry Said
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To the Editor: Dent and Panieri1 review current knowledge
about screening for breast cancer, pointing out that self-
examination appears to be ineffective, while clinical
examination is unproven.
They wade through the treacherous marsh of literature on
screening mammography and emerge with the opinion that
mammography reduces mortality from breast cancer, although
at a considerable cost — both financial and (for the victims of
mammography’s high false-positive rate) traumatic.
Had they been content to remind those of us in the
‘screening industry’ of our duty to correctly inform our
patients of both the strengths and weaknesses of our
examinations, I would have considered the editorial to be a
useful contribution to the literature.
However, they propose an alternative regimen for breast
cancer screening that I find hard to fathom. The discredited
self-examination is to give way to . . . self-examination, but this
time with an injection of mystical ‘breast awareness’ to boost
its effectiveness.
Mammography is to be done every third year. Simple
arithmetic suggests that when a screening examination is done
at intervals longer than the average lead time (2 years in the
case of mammography), its effectiveness will be markedly
reduced. To address mammography’s weak points (expense
and false positives) in this manner is like negotiating a special
deal with an armed response company to monitor your house
every third night, thus reducing costs and ensuring that you
are not disturbed by false alarms on the other two nights.
Women must be given enough information to make an
informed decision about screening mammography. Some will
opt out; that is their prerogative. For those who choose to have
screening mammograms, we should do them properly: until
further  research defines subgroups, possibly based on age or
genetic profile, who can expect to get tumours of a more
indolent nature than average, properly means annually.
Russell Whitehorn
Lake, Smit and Partners
Durban
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Professor Dent and Dr Panieri reply: Many years ago this
journal ran a regular provocative column entitled ‘Klip in die
bos’, analogous to the expression ‘shake the tree’. In the case of
our editorial, much emerged from the foliage. We are pleased
to respond.
At the outset we must state that we never denied the
scientific evidence that mammographic screening saves lives,
writing unequivocally and strongly that ‘. . . it must be
regarded as incontrovertibly evident that mammographic
screening saves women’s lives’. We also concluded that
‘mammography was probably a good thing to do’. The issues
we raised — which provoked the ire of the correspondence
above — were the frequency, cost and harms of the procedure.
The final red flag to the correspondent bulls was no doubt our
citing Richard Smith, Editor of the British Medical Journal, who
made an editorial stab at ‘the screening industry’. This perhaps
struck a chord somewhere.
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